Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer

Clinical Breast Cancer

Volumn 14, Issue 2, 2014, Pages 85-93

  Palmieri, Carlo ^a,b,c,d   Misra, Vivek ^e   Januszewski, Adam ^a   Yosef, Hosney ^f   Ashford, Richard ^g   Keary, Ian ^h   Davidson, Neville ⁱ  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^g MOUNT VERNON CANCER CENTRE   (United Kingdom)

^h Strategen Limited   (United Kingdom)

ⁱ Helen Rollason Research Laboratory   (United Kingdom)

Author keywords

Advanced; Anthracycline; Cardiotoxicity; Chemotherapy; Rechallenge

Indexed keywords

DOXORUBICIN; EPIRUBICIN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NONPEGYLATED LIPOSOMAL DOXORUBICIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL PRACTICE; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; DRUG USE; DYSPNEA; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; VERY ELDERLY; VOMITING;

ADVANCED; ANTHRACYCLINE; CARDIOTOXICITY; CHEMOTHERAPY; RECHALLENGE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84896392548     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.10.011     Document Type: Article

References (18)

1. J. O'Shaughnessy, C. Twelves, and M. Aapro Treatment for anthracycline-pretreated metastatic breast cancer Oncologist 7 suppl 6 2002 4 12 (Pubitemid 36008991)
2. National Institute for Health and Care Excellence. CG81: Advanced Breast Cancer: Diagnosis and Treatment. 2009. Available at: http://publications.nice. org.uk/advanced-breast-cancer-cg81. Accessed: November 2012.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
4. R. Fossati, C. Confalonieri, and V. Torri et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systemic review of published randomised trials involving 31,510 women J Clin Oncol 16 1998 3439 3460 (Pubitemid 28481644)
5. R. Fossati, F. Confalonieri, and V. Torri et al. Chemotherapy with and without anthracycline (in reply) J Clin Oncol 18 2000 1392 1393
6. C. Palmieri, J. Krell, and C.R. James et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer Nat Rev Clin Oncol 7 2010 561 574
7. R.E. Coleman, G. Bertelli, and T. Beaumont et al. UK guidance document: treatment of metastatic breast cancer Clin Oncol (R Coll Radiol) 24 2012 169 176
8. S. Beslija, J. Bonneterre, and H.J. Burstein et al. Third consensus on medical treatment of metastatic breast cancer Ann Oncol 20 2009 1771 1785
9. P. Barret-Lee, J.M. Dixon, and C. Farrell et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk Ann Oncol 20 2009 816 827
10. G. Batist, G. Ramakrishnan, and C.S. Rao et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer J Clin Oncol 19 2001 1444 1454 (Pubitemid 32202552)
11. S. Chan, N. Davidson, and E. Juozaityte et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer Ann Oncol 15 2004 1527 1534 (Pubitemid 39409744)
12. E.C. van Dalen, E.M. Michiels, and H.N. Caron et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients Cochrane Database Syst Rev 5 2010 CD005006
13. G. Batist, L. Harris, and N. Azarnia et al. Improved anti-tumor response rate with decreased cardiotoxicity of nonpegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis Anticancer Drugs 17 2006 587 595 (Pubitemid 44309976)
14. L. Harris, G. Batist, and R. Belt et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Cancer 94 2002 25 36 (Pubitemid 34049039)
15. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). Available at: http://ctep.cancer. gov/protocolDevelopment/electronic-applications/ctc.htm#ctc-40. Accessed: November 2012.
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Peto R., and C. Davies et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 2012 432 444
17. H. Roché, P. Fumoleau, and M. Spielmann et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial J Clin Oncol 24 2006 5664 5671 (Pubitemid 46631307)
18. P. Ellis, P. Barrett-Lee, and L. Johnson et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial Lancet 373 2009 1681 1692